

SGXNet

Create 'General Announcement' Announcement

Issuer & Securities

Issuer/ Manager

THE TRENDLINES GROUP LTD.

Securities

Name	ISIN	Stock Code
THE TRENDLINES GROUP LTD.	IL0011328858	42T

Stapled Security

No

Announcement Details

Announcement Sub Title

PRESS RELEASE: TRADING DEBUT FOR TRENDLINES AS THE 100th LISTING ON CATALIST

Submitted By (Co./ Ind. Name)

Lynn Wan Tiew Leng

Designation

Joint Company Secretary

Contact Details

6230 9507

Effective Date and Time of the event
Price Sensitivity

Yes

Description (Please provide a detailed description of the event in the box below)

Please see attached.

Attachments

For Public Dissemination

PressRelease_TrendlinesFirstDayTrading_26112015.pdf

Note: *** This is a computer generated for your internal information only. The information contained herein is not guaranteed as to its accuracy or completeness. No rights can be conferred from this. ***

For Immediate Release

Trading Debut for Trendlines as the 100th Listing on Catalist

- Stock opened at S\$0.34
- Approximately 26.6 million shares changed hands, market capitalisation of S\$157.7 million as at close of market today
- As the 100th company listed on the Catalist Board of SGX-ST, Trendlines will leverage on Singapore as a platform for accelerated growth

Singapore, 26 November 2015 – The Trendlines Group Ltd. (“Trendlines”, SGX:42T), an Israeli company focused on developing technology-based companies in the medical and agricultural fields, debuted today on the Catalist board of Singapore Exchange Securities Trading Limited (the “SGX-ST”). The stock opened at S\$0.34 on the first day of trading.

A total of approximately 26.6 million shares changed hands today with a turnover of approximately S\$8.9 million. The market capitalisation as at the close of market today was S\$157.7 million.

Commenting on the first day of trading, Todd Dollinger, Co-Chairman and Co-CEO of Trendlines, said, *“The official listing of The Trendlines Group on the SGX-ST marked a significant milestone in our brief history. We are also honoured to be the 100th company listed on the Catalist board of SGX-ST. We believe Singapore offers a sophisticated infrastructure, a favourable ecosystem and an established capital market platform for our business in developing medical and agricultural technology companies. We look forward to leveraging on these facilities to accelerate Trendlines’ growth.”*

Steve Rhodes, Co-Chairman and Co-CEO of Trendlines, added, *“The listing will also provide many investors with the ability to participate in our growth journey. We appreciate the trust from investors and the level of interest from the market in our business model as well as the exposure to the medical and agricultural technology business. In return, we are committed to continuously enhancing the market’s understanding of our business through timely and effective communication with the investment community, while striving to create and develop companies to improve the human condition.”*

Trendlines received strong interest from new investors and raised gross proceeds of S\$25,000,800, including S\$7,100,000 from the Company’s cornerstone investor, B. BRAUN Melsungen AG, a healthcare supplier with global sales of €5.43 billion.

- END -

About The Trendlines Group Ltd.

The Trendlines Group Ltd. (the **“Company”**) and together with its subsidiaries (the **“Group”**), focuses on developing technology-based companies in the medical and agricultural fields. The Group creates and develops companies in accordance with its mission to improve the human condition. To this end, the Group discovers, invests in, incubates and provides services to life sciences companies in the fields of medical and agricultural technologies.

The Group operates principally through its two operating subsidiaries, namely, Trendlines Medical – Misgav Ltd. (**“Trendlines Medical”**) and Trendlines Agtech – Mofet Ltd. (**“Trendlines Agtech”**), as well as through its own internal innovation centre, Trendlines Labs. Trendlines Medical focuses on the discovery and development of novel and disruptive medical devices and technologies while Trendlines Agtech focuses on the discovery and development of new agricultural and food technologies. Through Trendlines Labs, the Group engages in research and development activities to create new technologies, either as principal or in collaboration with global and local companies and partners, to address unmet market needs.

Issued for and on behalf of The Trendlines Group Ltd.

By Financial PR Pte Ltd.

For more information, please contact:

Romil SINGH / Reyna MEI

romil@financialpr.com.sg / reyna@financialpr.com.sg

Tel: (65) 6438 2990, Fax: (65) 6438 0064

IMPORTANT NOTICE

Capitalised terms used herein shall, unless otherwise defined, bear the same meanings assigned to them in the Offer Document (as defined herein).

This news release is for informational purposes only and does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities of The Trendlines Group Ltd. (“**Company**”) nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever. The summary information herein does not purport to be complete and should be read in conjunction with, and is qualified in its entirety by the detailed information in the final offer document of the Company dated 16 November 2015 (“**Offer Document**”) that has been registered by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”), acting as agent on behalf of the Monetary Authority of Singapore on 16 November 2015. Information contained in this news release does not constitute part of the Offer Document. No person shall be bound to enter into any contract or binding legal commitment and no monies or other form of consideration is to be accepted on the basis of this news release. No offer or agreement shall be made on the basis of this news release to purchase or subscribe for any securities to which this news release relates. Any decision to purchase or subscribe for the shares of the Company (“**Shares**”) should be made solely on the basis of information contained in the Offer Document after seeking appropriate professional advice, and no reliance should be placed on any information other than that contained in the Offer Document. The information in this news release should not be relied upon as representation or warranty of the Company.

This news release may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future events, actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors, such as known and unknown risks and uncertainties, and assumptions. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward- looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this news release only.

None of the Company, PrimePartners Corporate Finance Pte. Ltd. or any of their respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this news release or its contents or otherwise arising in connection with this news release, to the extent permitted by law.

Neither this news release nor any of its content may be used without the prior written consent of the Company. The Company requires you who have come into possession with this news release to inform yourself about and to observe such restriction at your own expense and without liability to the Company. By reading this news release, you agree to be bound by the limitations and restrictions set out herein.

A printed copy of the Offer Document may be obtained on request, subject to availability, during normal office hours from the office of PrimePartners Corporate Finance Pte. Ltd. at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318. An electronic copy of the Offer Document is also available on the SGX-ST website at <http://www.sgx.com>.

The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist.

The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.